Her laboratory is located at the Child & Family Research Institute where she coordinates the High Content Screening Program. Dr. Dunn is also the CEO and Founder of Phoenix Molecular Diagnostics, a spin-off company established in 2012. Over the past decade, she has had two successful projects with the Centre for Drug Research and Development which have laid the foundation for the therapeutic drug development in oncology.